The popularity of Viagra initially sparked a surge for pharma, however recent shifts present a murky scenario for shareholders. Off-patent alternatives are eroding profits, and ongoing legal battles add additional risk to the situation. While specific companies might still see gains from complementary offerings, the general trajectory suggests a… Read More